Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAR-LLD
- Development stage
- Unknown
- Lead developer
- Starton Therapeutics
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
STAR-LLD is a proprietary formulation of lenalidomide designed for continuous subcutaneous (SC) delivery using an ambulatory infusion device. Developed by Starton Therapeutics, this therapy aims to provide sustained low-dose exposure to lenalidomide, in contrast to the traditional oral pulsatile dosing (as with Revlimid). The continuous delivery approach maintains steady-state drug levels while minimizing peak concentrations, which may reduce hematologic toxicity and improve tolerability. Preclinical and early clinical studies have demonstrated that STAR-LLD achieves biologically active drug levels with improved safety—no grade 3/4 hematologic toxicities were observed in Phase 1b trials for relapsed/refractory multiple myeloma patients. Efficacy signals include high overall response rates and tumor shrinkage superior to daily oral dosing in animal models. The primary indications under investigation are multiple myeloma and chronic lymphocytic leukemia[1][3][5][6][7][8][9].
- Brand names
- STAR-LLD
- Other names
- STAR-LLDcontinuous delivery lenalidomidesubcutaneous lenalidomide infusion
02
Targets
CRBN (Cereblon)
Beyond the preview
Go deeper on STAR-LLD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAR-LLD.